Patents by Inventor Kim L. O'Neill

Kim L. O'Neill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-cancer activity of an anti-thymidine kinase monoclonal antibody
    Patent number: 7837998
    Abstract: Monoclonal antibodies to thymidine kinase 1 are disclosed which are useful in methods of detecting, diagnosing, and treating cancer.
    Type: Grant
    Filed: May 20, 2005
    Date of Patent: November 23, 2010
    Inventors: Nathaniel Lallatin, Kim L. O'Neill
  • Anti-Cancer Activity of an Anti-Thymidine Kinase Monoclonal Antibody
    Publication number: 20100266495
    Abstract: Methods of diagnosing and treating cancers that overexpress thymidine kinase 1 on their cell surfaces are provided. These methods utilize monoclonal antibodies that bind specifically to thymidine kinase 1 to inhibit or prevent proliferation of the cancer cells.
    Type: Application
    Filed: April 26, 2010
    Publication date: October 21, 2010
    Applicant: Brigham Young University
    Inventor: Kim L. O'Neill
  • Anti-viral activity of an anti-thymidine kinase monoclonal antibody
    Patent number: 7311906
    Abstract: Monoclonal antibodies to thymidine kinase 1 are disclosed which are useful in methods of detecting, diagnosing, and treating viral infection.
    Type: Grant
    Filed: April 28, 2005
    Date of Patent: December 25, 2007
    Assignee: Brigham Young University
    Inventors: Nathaniel Lallatin, Kim L. O'Neill
  • Monoclonal antibodies to thymidine kinase 1 and uses in diagnostic and therapeutic applications
    Patent number: 5698409
    Abstract: The invention provides a method for the purification of a mammalian thymidine kinase 1. Also provided is a purified mammalian TK1, obtained from Raji cells, that is stable in the absence of stabilizing agents, has a molecular weight of approximately 100 kD and exhibits enzyme activity associated with the native 100 kD tetrameric species of TK1 but not the monomeric subunit. This purified TK1 was used to prepare a monoclonal antibody which inhibited TK1 enzyme activity. This anti-TK1 monoclonal antibody was used in methods for the diagnosis of cancer and for predicting the recurrence of cancer.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: December 16, 1997
    Assignee: Brigham Young University
    Inventor: Kim L. O'Neill